Clinicopathologic characteristics: At last, 1018 patients with elderly small intestine adenocarcinoma were enrolled, the flow chart of screening is shown in Fig. 1, of which 765 (75.15%) and 253 (24.85%) respectively in surgery and non-surgery group. The clinicopathologic characteristics before and after PSM in this study were all shown in Table 1. Patients in non-surgery group were diagnosed at older age (age ≥ 75 years, 57.31% vs 46.01%, p < 0.0001), represented larger proportion of advantaged stage disease (stageⅣ,43.48% vs 15.16%) and smaller proportion of well/moderately differentiated (grade I-Ⅱ,37.94% vs 61.44%, p < 0.0001), were more likely to receive radiation (17.39% vs 7.32%, p < 0.0001) and chemotherapy (50.59% vs 41.18%, p = 0.009). tumors located at duodenum presented 91.70% and 51.17% in non-surgery and surgery group respectively, besides, adenocarcinoma was the most common pathological type in the two groups. Compared with surgery group, non-surgery group had less mucinous adenocarcinoma and more signet ring cell carcinoma (3.56%, 3.16% vs 11.37%, 2.88%, p = 0.001). After PSM, there were 147 patients in each group, except for tumor site (p = 0.001), there exist no statistical differences in remaining variable.
Table 1
Comparison of baseline variables between surgery and non-surgery group in the original and matched datasets
Variables
|
Total
|
Before propensity score matching
|
Total
|
After propensity score matching
|
|
N = 1018(%)
|
Without surgery N = 253(%)
|
Surgery N = 765(%)
|
P value
|
N = 294(%)
|
Without surgery N = 147(%)
|
SurgeryN = 147(%)
|
P value
|
Age
|
|
|
|
<0.0001
|
|
|
|
0.502
|
65-74years
|
|
108(42.69%)
|
413(53.99%)
|
|
|
71(48.30%)
|
61(41.50%)
|
|
75-84years
|
|
97(38.34%)
|
280(36.60%)
|
|
|
58(39.46%)
|
66(44.90%)
|
|
≥ 85years
|
|
48(18.97%)
|
72(9.41%)
|
|
|
18(12.24%)
|
20(13.61%)
|
|
Sex
|
|
|
|
0.772
|
|
|
|
0.062
|
Male
|
|
128(50.59%)
|
378(49.41%)
|
|
|
83(56.46%)
|
67(45.58%)
|
|
Female
|
|
125(49.41%)
|
387(50.59%)
|
|
|
64(43.54%)
|
80(54.42%)
|
|
Race
|
|
|
|
0.536
|
|
|
|
0.425
|
Black
|
|
44(17.39%)
|
119(15.56%)
|
|
|
28(19.05%)
|
24(16.33%)
|
|
White
|
|
187(73.91%)
|
591(77.25%)
|
|
|
109(74.15%)
|
107(72.79%)
|
|
Other
|
|
22(8.70%)
|
55(7.19%)
|
|
|
10(6.80%)
|
16(10.88%)
|
|
Primary site
|
|
|
|
<0.0001
|
|
|
|
0.001
|
Duodenum
|
|
232(91.70%)
|
382(49.93%)
|
|
|
130(88.44%)
|
120(81.63%)
|
|
Ileum
|
|
5(1.98%)
|
137(17.91%)
|
|
|
4(2.72%)
|
15(10.20%)
|
|
Jejunum
|
|
3(1.19%)
|
145(18.95%)
|
|
|
2(1.36%)
|
9(6.12%)
|
|
Small intestine, NOS
|
|
13(5.14%)
|
101(13.20%)
|
|
|
11(7.48%)
|
3(2.04%)
|
|
Grade
|
|
|
|
<0.0001
|
|
|
|
0.336
|
I- II
|
|
96(37.94%)
|
470(61.44%)
|
|
|
72(48.98%)
|
68(46.26%)
|
|
III
|
|
68(26.88%)
|
246(32.16%)
|
|
|
44(29.93%)
|
52(35.37%)
|
|
IV
|
|
1(0.40%)
|
15(1.96%)
|
|
|
0(0%)
|
4(2.72%)
|
|
Unknown
|
|
88(34.78%)
|
34(4.44%)
|
|
|
31(21.09%)
|
23(15.65%)
|
|
Marital status
|
|
|
|
0.246
|
|
|
|
0.103
|
Married
|
|
133(52.57%)
|
448(58.56%)
|
|
|
83(56.46%)
|
65(44.22%)
|
|
Unmarried
|
|
111(43.87%)
|
292(38.17%)
|
|
|
61(41.50%)
|
77(52.38%)
|
|
Unknown
|
|
9(3.56%)
|
25(3.27%)
|
|
|
3(2.04%)
|
5(3.40%)
|
|
Histology
|
|
|
|
0.001
|
|
|
|
0.296
|
Adenocarcinoma
|
|
236(93.28%)
|
656(85.75%)
|
|
|
136(92.52%)
|
131(89.12%)
|
|
Mucinous adenocarcinoma
|
|
9(3.56%)
|
87(11.37%)
|
|
|
5(3.40%)
|
11(7.48%)
|
|
Signet ring cell carcinoma
|
|
8(3.16%)
|
22(2.88%)
|
|
|
6(4.08%)
|
5(3.40%)
|
|
AJCC 6th
|
|
|
|
<0.0001
|
|
|
|
0.424
|
I- II
|
|
110(43.48%)
|
355(46.41%)
|
|
|
73(49.66%)
|
84(57.14%)
|
|
III
|
|
33(13.04%)
|
294(38.43%)
|
|
|
29(19.73%)
|
26(17.69%)
|
|
IV
|
|
110(43.48%)
|
116(15.16%)
|
|
|
45(30.61%)
|
37(25.17%)
|
|
Radiotherapy
|
|
|
|
<0.0001
|
|
|
|
0.880
|
Yes
|
|
44(17.39%)
|
56(7.32%)
|
|
|
26(17.69%)
|
28(19.05%)
|
|
No/unkwon
|
|
209(82.61%)
|
709(92.68%)
|
|
|
121(82.31%)
|
119(80.95%)
|
|
Chemotherapy
|
|
|
|
0.009
|
|
|
|
0.348
|
Yes
|
|
128(50.59%)
|
315(41.18%)
|
|
|
70(47.62%)
|
61(41.50%)
|
|
No/unkwon
|
|
125(49.41%)
|
450(58.82%)
|
|
|
77(52.38%)
|
86(58.50%)
|
|
Survival analyses and related prognostic indicators before PSM: Overall, small intestine adenocarcinoma had poor survival outcomes, the median OS was 16 months, the 5-year OS and CSS rates were 26.5% and 33.3% respectively. We compared 3- and 5-year OS and CSS rate between surgery and non-surgery group. Kaplan-Meier plots exhibits in Fig. 1a and b. In surgery, the 3- and 5-year OS rates were 45.6% and 34.70%, 6.34% and 1.35% in non-surgery group respectively, the 3- and 5-years CSS rates in surgery group were 51.4% and 42.1%, 9.49% and 3.0% in non-surgery group respectively. Related survival prognostic indicators including univariate and multivariate analyses were shown in Table 2 and Table 3. In univariate analyses, age, primary site, grade, histology type, tumor stage, surgery, radiation and chemotherapy were predictors for OS and CSS. In multivariate analyses, age (75-84years, HR = 1.192, p = 0.027,95%CI:1.021–1.393); ≥85years, HR = 1.267, p = 0.049, 95%CI:1.001–1.604), primary site (small intestine, NOS, HR = 1.290, p = 0.036, 95%CI:1.017–1.636), grade (grade III, HR = 1.289, p = 0.002, 95%CI: 1.097–1.515; unknown: HR = 0.777, p = 0.038, 95%CI: 0.611–0.986), tumor stage (stage III: HR = 2.010, p < 0.0001, 95% CI:1.673–2.416; stage IV: HR = 3.185, p < 0.0001, 95%CI:2.571–3.947), surgery (no/unknown: HR = 3.245, p < 0.0001, 95%CI: 2.625–4.011), chemotherapy (no/unknown: HR = 1.334, p = 0.001, 95%CI:1.122–1.585) were independent prognostic factors for OS; while primary site (Small intestine, NOS, HR = 1.309, p = 0.048, 95%CI:1.003–1.709), grade (grade III, HR = 1.391, p < 0.0001, 95%CI:1.165–1.660; unknown, HR = 1.309, p = 0.048, 95%CI:1.003–1.709), tumor stage (stage III, HR = 2.479, p < 0.0001, 95%CI:2.012–3.055; stage IV, HR = 3.837, p < 0.0001, 95%CI:3.027–4.864), surgery (no/unknown, HR = 3.437, p < 0.0001, 95%CI:2.728–4.331), radiotherapy (no/unknown, HR = 0.750, p = 0.027, 95%CI:0.580–0.968) and chemotherapy (no/unknown, HR = 1.287, p = 0.006, 95%CI:1.073–1.543) were independent prognostic factors for CSS.
Table 2
Univariates and multivariate analyses of overall survival (OS) in eligible patients.
Variables
|
N(%)
|
Univariate analysis
|
Multivariate analysis
|
|
|
HR(95%CI)
|
P value
|
HR(95%CI)
|
P value
|
Age
|
|
|
0.002
|
|
0.036
|
65-74years
|
521(51.18%)
|
refference
|
1
|
refference
|
1
|
75-84years
|
377(37.03%)
|
1.172(1.008–1.363)
|
0.039
|
1.192(1.021–1.393)
|
0.027
|
≥85years
|
120(11.79%)
|
1.456(1.174–1.805)
|
0.001
|
1.267(1.001–1.604)
|
0.049
|
Sex
|
|
|
|
|
NI
|
Male
|
506(49.71%)
|
refference
|
1
|
|
|
Female
|
512(50.29%)
|
0.915(0.796–1.052)
|
0.213
|
|
|
Race
|
|
|
0.914
|
|
NI
|
Black
|
163(16.01%)
|
refference
|
1
|
|
|
White
|
778(76.42%)
|
1.013(0.838–1.226)
|
0.891
|
|
|
Other
|
77(7.56%)
|
1.066(0.778–1.444)
|
0.678
|
|
|
Primary site
|
|
|
<0.0001
|
|
0.074
|
Duodenum
|
614(60.31%)
|
refference
|
1
|
refference
|
1
|
Jejunum
|
142(13.95%)
|
0.673(0.545–0.831)
|
<0.0001
|
0.893(0.708–1.127)
|
0.341
|
Ileum
|
148(14.54%)
|
0.710(0.574–0.877)
|
0.002
|
0.987(0.780–1.249)
|
0.913
|
Small intestine, NOS
|
114(11.20%)
|
0.979(0.785–1.223)
|
0.854
|
1.290(1.017–1.636)
|
0.036
|
Grade
|
|
|
<0.0001
|
|
<0.0001
|
I-II
|
566(55.60%)
|
refference
|
1
|
refference
|
1
|
III
|
314(30.84%)
|
1.437(1.230–1.679)
|
<0.0001
|
1.289(1.097–1.515)
|
0.002
|
IV
|
16(1.57%)
|
1.063(0.599–1.887)
|
0.835
|
1.529(0.855–2.735)
|
0.152
|
Unknown
|
122(11.98%)
|
1.580(1.276–1.957)
|
<0.0001
|
0.777(0.611–0.986)
|
0.038
|
Marital status
|
|
|
0.053
|
|
0.341
|
Married
|
581(57.07%)
|
refference
|
1
|
refference
|
1
|
Unmarried
|
403(39.59%)
|
1.181(1.024–1.362)
|
0.23
|
1.113(0.959–1.292)
|
0.157
|
Unknown
|
34(3.34%)
|
0.900(0.592–1.369)
|
0.624
|
0.968(0.633–1.479)
|
0.88
|
Histology
|
|
|
0.002
|
|
0.151
|
Adenocarcinoma
|
892(87.62%)
|
refference
|
1
|
refference
|
1
|
Mucinous adenocarcinoma
|
96(9.43%)
|
0.790(0.615–1.013)
|
0.063
|
0.964(0.744–1.248)
|
0.781
|
Signet ring cell carcinoma
|
30(2.95%)
|
1.743(1.193–2.547)
|
0.004
|
1.467(0.988–2.178)
|
0.057
|
AJCC 6th stage
|
|
|
<0.0001
|
|
<0.0001
|
I- II
|
465(45.68%)
|
refference
|
1
|
refference
|
1
|
III
|
327(32.12%)
|
1.522(1.291–1.796)
|
<0.0001
|
2.010(1.673–2.416)
|
<0.0001
|
IV
|
226(22.20%)
|
3.399(2.838–4.070)
|
<0.0001
|
3.185(2.571–3.947)
|
<0.0001
|
Surgery
|
|
|
|
|
|
Yes
|
765(75.15%)
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
253(24.85%)
|
3.279(2.801–3.839)
|
<0.0001
|
3.245(2.625–4.011)
|
<0.0001
|
Radiotherapy
|
|
|
|
|
|
Yes
|
100(9.82%)
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
918(90.18%)
|
0.794(0.633–0.994)
|
0.044
|
0.853(0.666–1.093)
|
0.21
|
Chemotherapy
|
|
|
|
|
|
Yes
|
443(43.52%)
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
575(56.48%)
|
0.838(0.728–0.964)
|
0.014
|
1.334(1.122–1.585)
|
0.001
|
Table 3
Univariates and multivariate analyses of Cancer-specific survival (CSS) in eligible patients.
Variables
|
Univariate analysis
|
|
Multivariate analysis
|
|
|
HR(95%CI)
|
P value
|
HR(95%CI)
|
P value
|
Age
|
|
0.192
|
|
NI
|
65-74years
|
refference
|
1
|
|
|
75-84years
|
1.139(0.965–1.344)
|
0.125
|
|
|
≥85years
|
1.192(0.927–1.533)
|
0.17
|
|
|
Sex
|
|
|
|
NI
|
Male
|
refference
|
1
|
|
|
Female
|
0.948(0.812–1.107)
|
0.5
|
|
|
Race
|
|
0.772
|
|
NI
|
Black
|
refference
|
1
|
|
|
White
|
1.082(0.872–1.343)
|
0.473
|
|
|
Other
|
1.062(0.753-1.500)
|
0.731
|
|
|
Primary site
|
|
<0.0001
|
|
0.07
|
Duodenum
|
refference
|
1
|
refference
|
1
|
Jejunum
|
0.614(0.483–0.782)
|
<0.0001
|
0.850(0.654–1.104)
|
0.223
|
Ileum
|
0.669(0.527–0.849)
|
<0.0001
|
0.987(0.756–1.289)
|
0.926
|
Small intestine, NOS
|
0.925(0.721–1.186)
|
0.538
|
1.309(1.003–1.709)
|
0.048
|
Grade
|
|
<0.0001
|
|
<0.0001
|
I-II
|
refference
|
1
|
refference
|
1
|
III
|
1.586(1.336–1.883)
|
<0.0001
|
1.391(1.165–1.660)
|
<0.0001
|
IV
|
1.102(0.587–2.069)
|
0.761
|
0.987(0.756–1.289)
|
0.118
|
Unknown
|
1.714(1.356–2.166)
|
<0.0001
|
1.309(1.003–1.709)
|
0.048
|
Marital status
|
|
0.123
|
|
NI
|
Married
|
refference
|
1
|
|
|
Unmarried
|
1.105(0.943–1.295)
|
0.218
|
|
|
Unknown
|
0.679(0.405–1.139)
|
0.142
|
|
|
Histology
|
|
0.003
|
|
0.219
|
Adenocarcinoma
|
refference
|
1
|
refference
|
1
|
Mucinous adenocarcinoma
|
0.792(0.600-1.045)
|
0.099
|
1.044(0.783–1.391)
|
0.769
|
Signet ring cell carcinoma
|
1.810(1.211–2.705)
|
0.004
|
1.451(0.953–2.208)
|
0.083
|
AJCC6th stage
|
|
<0.0001
|
|
<0.0001
|
I- II
|
refference
|
1
|
refference
|
1
|
III
|
1.965(1.628–2.370)
|
<0.0001
|
2.479(2.012–3.055)
|
<0.0001
|
IV
|
4.383(3.590–5.352)
|
<0.0001
|
3.837(3.027–4.864)
|
<0.0001
|
Surgery
|
|
|
|
|
Yes
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
3.412(2.877–4.048)
|
<0.0001
|
3.437(2.728–4.331)
|
<0.0001
|
Radiotherapy
|
|
|
|
|
Yes
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
0.688(0.544–0.872)
|
0.002
|
0.750(0.580–0.968)
|
0.027
|
Chemotherapy
|
|
|
|
|
Yes
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
0.680(0.582–0.794)
|
<0.0001
|
1.287(1.073–1.543)
|
0.006
|
Survival analyses and related prognostic indicators after PSM: After PSM, we compared 3- and 5-year OS and CSS rates between surgery and non-surgery group. Kaplan-Meier plots exhibits in Fig. 1c and d. Univariate and multivariate analyses were shown in Table 4 and Table 5. In univariate analyses, advantaged stage disease were risk factors for OS and CSS, besides, patients underwent surgery had better OS and CSS; signet ring cell carcinoma was an unfavorable predictor for OS, patients with no chemotherapy had better CSS. In multivariate analyses, tumor stage (stage III, HR = 1.691, p = 0.002, 95%CI:1.210–2.363; HR = 2.475, p < 0.0001, 95%CI:1.670–3.670; stage IV, HR = 2.449, p < 0.0001, 95%CI:1.808–3.317; HR = 3.715, p < 0.0001, 95%CI:2.494–5.533; respectively) and surgery (no/unknown, HR = 3.181, p < 0.0001, 95%CI:2.414–4.192; HR = 3.050, p < 0.0001, 95%CI:2.266–4.104; respectively) were independent prognostic factors for OS and CSS.
Table 4
Univariates and multivariate analyses of overall survival (OS) in matched dataset.
Variables
|
N(%)
|
Univariate analysis
|
Multivariate analysis
|
|
|
HR(95%CI)
|
P value
|
HR(95%CI)
|
P value
|
Age
|
|
|
0.674
|
|
NI
|
65-74years
|
132(44.90%)
|
refference
|
1
|
|
|
75-84years
|
124(42.18%)
|
0.890(0.680–1.164)
|
0.393
|
|
|
≥85years
|
38(12.93%)
|
0.992(0.666–1.477)
|
0.967
|
|
|
Sex
|
|
|
|
|
NI
|
Male
|
150(51.02%)
|
refference
|
1
|
|
|
Female
|
144(48.98%)
|
0.808(0.627–1.041)
|
0.1
|
|
|
Race
|
|
|
0.314
|
|
NI
|
Black
|
52(17.69%)
|
refference
|
1
|
|
|
White
|
216(73.47%)
|
1.161(0.832–1.619)
|
0.38
|
|
|
Other
|
26(8.84%)
|
0.849(0.504–1.431)
|
0.538
|
|
|
Primary site
|
|
|
0.144
|
|
NI
|
Duodenum
|
250(85.03%)
|
refference
|
1
|
|
|
Ileum
|
19(6.46%)
|
1.102(0.672–1.808)
|
0.7
|
|
|
Jejunum
|
11(3.74%)
|
0.479(0.213–1.080)
|
0.076
|
|
|
Small intestine, NOS
|
14(4.76%)
|
1.476(0.852–2.525)
|
0.166
|
|
|
Grade
|
|
|
0.112
|
|
NI
|
I-II
|
140(47.62%)
|
refference
|
1
|
|
|
III
|
96(32.65%)
|
1.177(0.887–1.561)
|
0.259
|
|
|
Ⅳ
|
4(1.36%)
|
0.337(0.083–1.366)
|
0.128
|
|
|
Unknown
|
54(18.73%)
|
0.828(0.583–1.174)
|
0.29
|
|
|
Marital status
|
|
|
0.559
|
|
NI
|
Married
|
148(50.34%)
|
refference
|
1
|
|
|
Separeted
|
138(46.94%)
|
0.875(0.678–1.128)
|
0.302
|
|
|
Unmarried
|
8(2.72%)
|
0.823(0.363–1.868)
|
0.641
|
|
|
Histology
|
|
|
0.12
|
|
0.35
|
Adenocarcinoma
|
267(90.82%)
|
refference
|
1
|
|
1
|
Mucinous adenocarcinoma
|
16(5.44%)
|
1.125(0.655–1.932)
|
0.669
|
1.008(0.586–1.736)
|
0.976
|
Signet ring cell carcinoma
|
11(3.74%)
|
1.939(1.024–3.672)
|
0.042
|
1.610(0.845–3.067)
|
0.148
|
AJCC 6th stage
|
|
|
<0.0001
|
|
<0.0001
|
I- II
|
157(53.40%)
|
refference
|
1
|
refference
|
1
|
III
|
55(18.71%)
|
1.686(1.209–2.353)
|
0.002
|
1.691(1.210–2.363)
|
0.002
|
IV
|
82(27.89%)
|
2.731(2.025–3.684)
|
<0.0001
|
2.449(1.808–3.317)
|
<0.0001
|
Surgery
|
|
|
|
|
|
Yes
|
147(50.00%)
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
147(50.00%)
|
3.311(2.518–4.353)
|
<0.0001
|
3.181(2.414–4.192)
|
<0.0001
|
Radiotherapy
|
|
|
|
|
NI
|
Yes
|
54(18.37%)
|
refference
|
1
|
|
|
No/unkwon
|
240(81.63%)
|
1.033(0.747–1.429)
|
0.845
|
|
|
Chemotherapy
|
|
|
|
|
NI
|
Yes
|
131(44.56%)
|
refference
|
1
|
|
|
No/unkwon
|
163(55.44%)
|
0.824(0.640–1.061)
|
0.133
|
|
|
Table 5
Univariates and multivariate analyses of Cancer-specific survival (CSS) in matched dataset.
Variables
|
Univariate analysis
|
Multivariate analysis
|
|
HR(95%CI)
|
P value
|
HR(95%CI)
|
P value
|
Age
|
|
0.463
|
|
NI
|
65-74years
|
refference
|
1
|
|
|
75-84years
|
0.862(0.645–1.153)
|
0.318
|
|
|
≥85years
|
0.790(0.498–1.255)
|
0.319
|
|
|
Sex
|
|
|
|
NI
|
Male
|
refference
|
1
|
|
|
Female
|
0.897(0.681–1.181)
|
0.44
|
|
|
Race
|
|
0.102
|
|
NI
|
Black
|
refference
|
1
|
|
|
White
|
1.351(0.924–1.977)
|
0.121
|
|
|
Other
|
0.876(0.480–1.596)
|
0.664
|
|
|
Primary site
|
|
0.207
|
|
NI
|
Duodenum
|
refference
|
1
|
|
|
Ileum
|
1.162(0.685–1.969)
|
0.578
|
|
|
Jejunum
|
0.475(0.195–1.156)
|
0.101
|
|
|
Small intestine, NOS
|
1.426(0.793–2.562)
|
0.236
|
|
|
Grade
|
|
0.054
|
|
NI
|
I-II
|
refference
|
1
|
|
|
III
|
1.357(0.966–1.907)
|
0.079
|
|
|
Unknown
|
0.793(0.515–1.221)
|
0.293
|
|
|
Marital status
|
|
0.193
|
|
NI
|
Married
|
refference
|
1
|
|
|
Separeted
|
0.791(0.599–1.046)
|
0.1
|
|
|
Unmarried
|
0.612(0.225–1.659)
|
0.334
|
|
|
Histology type
|
|
0.146
|
|
NI
|
Adenocarcinoma
|
refference
|
1
|
|
|
Mucinous adenocarcinoma
|
1.178(0.657–2.112)
|
0.583
|
|
|
Signet ring cell carcinoma
|
1.928(0.983–3.781)
|
0.056
|
|
|
AJCC stage group 6th edition
|
|
<0.0001
|
|
<0.0001
|
I- II
|
refference
|
1
|
refference
|
1
|
III
|
2.160(1.509–3.092)
|
<0.0001
|
2.475(1.670–3.670)
|
<0.0001
|
IV
|
3.293(2.385–4.547)
|
<0.0001
|
3.715(2.494–5.533)
|
<0.0001
|
Surgery
|
|
|
|
|
Yes
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
3.259(2.425–4.379)
|
<0.0001
|
3.050(2.266–4.104)
|
<0.0001
|
Radiotherapy
|
|
|
|
NI
|
Yes
|
refference
|
1
|
|
|
No/unkwon
|
0.955(0.675–1.349)
|
0.792
|
|
|
Chemotherapy
|
|
|
|
|
Yes
|
refference
|
1
|
refference
|
1
|
No/unkwon
|
0.693(0.526–0.913)
|
0.009
|
1.372(0.975–1.930)
|
0.07
|